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Monokine Induced by Interferon-g (MIG), a CXC chemokine, is a potent inducer of T-cell chemotaxis
and activation and has been implicated in the host response to viral infections and tumor immunity as
well as in the pathogenesis of autoimmunity and transplant rejection. Although it is known that the
Toll-Like Receptor-4 (TLR-4) ligand LPS synergizes with IFN-g to induce MIG expression in
macrophages, the molecular mechanisms responsible for the synergy have yet to be elucidated.
We determined that the marked synergy between LPS and IFN-g on MIG mRNA expression in mouse
macrophages is a result of LPS-induced NF-kB and IFN-g-induced STAT. The synergy was not
dependent on new protein synthesis, was independent of TNF-a, and occurred at the level of gene
transcription. We identiﬁed 2 NF-kB sites located at 2154 and 2129 of the MIG promoter proximal to
the g-responsive element that mediated this effect. Finally, we demonstrated that other TLR ligands
(zymosan, double stranded RNA and CpG) synergized with IFN-g to induce MIG in an NF-kB
dependent fashion. These data emphasize the ability of bacterial and viral products to activate/modify
immune responses and promote adaptive T cell immunity through the NF-kB pathway.
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INTRODUCTION
The Toll-Like receptors (TLRs) play a critical role in the
induction of the innate immune response. These receptors
have evolved to recognize pathogen associated mole-
cular patterns that are integral components of lipo-
polysaccharides, zymosan, ﬂagellin, unmethylated CpG
and double stranded RNA (dsRNA) (Takeuchi and Akira,
2001; Dunne and O’Neill, 2003). In this fashion, the host
can rapidly respond to infections by elaborating cytokines,
chemokines and inﬂammatory enzymes as well as reactive
oxygen species. TLR engagement also activates macro-
phages and dendritic cells, increasing their cell surface
expression of co-stimulatory and adhesion molecules
(Jones et al., 2001; Dunne and O’Neill, 2003). Thus TLR
ligation heralds infection (danger) and induces the
necessary second signals for adaptive T cell immunity.
Activated macrophages play an essential role in
inﬂammation by releasing of a variety of mediators
including reactive oxygen and nitrogen species, proteases,
chemokines, cytokines and growth factors (Nathan, 1987).
IFN-g modulates macrophage effector functions and
regulates the inﬂammatory response of organisms to host
insults such as endotoxin by enhancing macrophage
microbiocidal and tumoricidal activity as well as speciﬁc
chemokine production (Luster et al., 1985; Maeyer and
Maeyer-Guignard, 1992). LPS, the structural component
of gram-negative bacteria, is one of the most potent
microbial activators of inﬂammation and inducers of
macrophage cytokines and chemokines. Together IFN-g
and LPS can synergizes to further potentate the production
of endogenous mediators of inﬂammation (Farber,
1992,1993; Gasperini et al., 1999).
IFN-g induces macrophage expression of the chemo-
kine Monokine Induced by interferon-g (MIG) (Farber,
1990,1992,1993; Liao et al., 1995; Gasperini et al.,
1999). This chemokine is up-regulated in chronic
inﬂammation as well as in viral and protozoan infections
and its expression correlates with IFN-g expression
(Amichay et al., 1996). In addition to its roles in T-cell
trafﬁcking, chemotaxis and activation, MIG is one of the
CXC chemokines with angiostatic properties (Liao et al.,
1995; Strieter et al., 1995; Loetscher et al., 1996). Thus,
MIG may play an important role in regulating tissue
granulation and remodeling as well as slowing down
tumor growth by inhibiting angiogenesis. To date, IFN-g
alone has been identiﬁed as an inducer of MIG in
macrophages (Farber, 1990). While several investigators
have described the synergistic enhancement of IFN-g
induced MIG expression by LPS in macrophages,
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unknown (Farber, 1990; Gasperini et al., 1999).
In this report we demonstrate that the maximal
production of MIG by macrophages is the result of the
collaboration between Toll-like receptor engagement and
IFN-g. We deﬁne the molecular mechanisms responsible
for the striking synergy by which LPS-induced NF-kB
(TLR4 ligation), acting in conjunction with IFN-g,
regulates the immune response by inﬂuencing the
expression of speciﬁc chemokines. In addition, we extend
our ﬁndings to other TLR ligands showing that they too
can synergizewith IFN-g, in an NF-kB dependent fashion,
to enhance MIG production.
MATERIAL AND METHODS
Cells
MH-S cells, a mouse alveolar macrophage cell line,
were purchased from American Type Culture Collection,
Rockville, MD. (Mbawuike and Herscowitz, 1989). Cells
were maintained in RPMI 1640 supplemented with
10% heat-inactivated low-LPS fetal bovine serum, 1%
penicillin-streptomycin and 1% glutamine (Bioﬂuids,
Rockville, MD) at 378C under 5% CO2. Thioglycollate-
elicited peritoneal macrophages were obtained from
TNF-a null, p50 NF-kB null and control mice (Jackson,
Bar Harbor, ME) as previously described (Horton et al.,
1998).
Chemicals and Reagents
Recombinant mouse IFN-g (speciﬁc activity, 3:0 £
105 U=ml with endotoxin level less than 0.2ng/mg) was
purchased from Invitrogen. Proteosome inhibitor-1,
Wortmannin and MEK inhibitor PD98059 were purchased
from Calbiochem, LaJolla, Ca. Cycloheximide, LPS
(pseudomonas aeroginosa serotype 10), zymosan and
dsRNAwere purchased from Sigma. CpG was synthesized
by Oligos Etc. Inc.
Northern Analysis of mRNA Production
RNA was extracted from conﬂuent cell monolayers of
MH-S cells via Trizol reagent (Invitrogen) or from
peritoneal macrophages with RNeasy (Qiagen) per
manufacturer’s guidelines. Northern blot analysis was
performed as described previously (Horton et al., 1998).
Preparation of Nuclear Extracts and Electrophoretic
Mobility Shift Assays
Nuclear extracts from MH-S cells were prepared as
previously described (Horton et al., 2002; Powell et al.,
1999). Electrophoretic mobility shift assays (EMSA) were
conducted using 6% polyacrylamide gels, as previously
described (Horton et al., 2002). Nuclear extracts (5mg)
were incubated at RT for 30min with 30,000cpm of
32P
end-labeled, double-stranded oligonucleotide probe (10–
50pg), 0.1–1mg of denatured salmon sperm DNA
(Invitrogen) and buffer prior to gel electrophoresis at
48C. The following dsDNA probes were used: 2154 site
gcagaaattccctgggatctgag, 2154M mutant gcagaaatt-
cAAtgggatctgag, 2129 site tagggttttccccaggacgatc and
2129M mutant tagggttttcAAcaggacgatc. Additionally,
dsDNA probes of the following consensus sequences were
used for cold competition analysis: NF-kB, tagggttttccc-
caggacgatc and STAT-1a, catgttatgcatattcctgtaagtg
(Santa Cruz Biotechnology). For supershift analysis,
nuclear extracts were simultaneously incubated with 1mg
of the indicated antibody and the labeled probe prior to
EMSA. The following antibodies were obtained from
Santa Cruz Biotechnology: STAT-1 p84/p91, NF-kB p50,
NF-kB p65 and NF-kB p52.
RNA and EMSA Analysis
Blots were developed on a STORM PhosphorImager
(Molecular Dynamics, Sunnyvale, CA). Quantiﬁcation of
bands was determined by the PhosphorImager using a
ﬁxed area with the object average program for determin-
ing the background (ImageQuant; Molecular Dynamics)
to account for inter-lane background variation.
Transient Transfections
Transient transfections of the MH-S cells with wild type and
mutated MIG promoter reporter constructs were performed
as previously described using lipofectamine 2000 per
manufacture guidelines (Invitrogen) (Horton et al., 2002).
LuciferaseexpressionwasmeasuredusingaDualLuciferase
Kit(Promega)andaZyluxfemtomasterFB-12luminometer.
Statistical Analysis
Statistical analysis was performed between groups using
an ANOVA factorial analysis program from Statview
(Abacus Concepts). A difference between groups of
p , 0:05 was considered signiﬁcant.
RESULTS
TLR Ligands Synergize with IFN-g to Induce MIG
mRNA Expression in Mouse Macrophages
Previously it has been reported that the TLR-4 ligand LPS
can synergize with IFN-g to induce MIG expression by an
unknown mechanism (Farber, 1992; Gasperini et al.,
1999; Sun et al., 2001). We further investigated the role of
other TLR ligands in inducing MIG expression with and
without IFN-g in macrophages. The alveolar macrophage
cell line, MH-S, was simultaneously stimulated with
the TLR ligands: zymosan 10mg/ml (TLR-2),
dsRNA 50ug/ml (TLR-3), LPS 10ng/ml (TLR-4) and
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(300U/ml) for 6h, total RNA was isolated and Northern
analysis performed (Fig. 1). Whereas IFN-g alone resulted
in minimal induction of MIG (note the typical MIG
mRNA doublet), none of the TLR ligands alone induced
MIG. In striking contrast however, there was marked
synergy between each of the TLR ligands tested and IFN-
g on the induction of MIG RNA. Similar results were
observed with peritoneal derived and bone marrow
derived primary macrophages (data not shown). Thus,
although TLR ligation in and of itself does not promote
MIG expression, in collaboration with IFN-g it markedly
enhances MIG production.
The TLR-4 Ligand LPS Synergizes with IFN-g to
Induce MIG mRNA Expression in Mouse
Macrophages in a Time and Dose Dependent Fashion
We further investigated the molecular mechanisms
mediating the synergy between the TLR-4 ligand LPS
and IFN-g on MIG expression by mouse macrophages.
MH-S alveolar macrophages were simultaneously
stimulated with LPS (10ng/ml) and IFN-g (300U/ml)
for varying time intervals and total RNAwas harvested for
Northern analysis. The synergy between LPS and IFN-g
on MIG expression was seen as early as 3h after
simultaneous stimulation, peaked after 6–9h and
decreased towards baseline after 24h of stimulation
(data not shown). Additionally, as expected, LPS failed to
independently induce and IFN-g only minimally induced
MIG mRNA expression at any time point.
We also determined the dose-response relationships for
HA and IFN-g induced MIG expression in macrophages.
Northern analysis for MIG was performed on total RNA
from MH-S macrophages stimulated with varying
concentrations of LPS with a constant concentration
of IFN-g (Fig. 2A). The synergy between LPS and IFN-g
on MIG gene expression occurred with as little as
0.1ng/ml LPS and was maximal at 1mg/ml LPS in the
presence of 300U/ml IFN-g. The converse experiment
was performed using a constant concentration of LPS
(10ng/ml) and varying the concentration of IFN-g
(Fig. 2B). The synergy between LPS and IFN-g occurred
with as little as 1U/ml IFN-g and was maximal at
1000U/ml IFN-g. Importantly, at lower doses of IFN-g,
which alone did not induce detectable MIG, LPS was able
to markedly upregulate MIG expression.
Cycloheximide does not Inhibit the Synergy between
the TLR-4 Ligand LPS and IFN-g on MIG Expression
in Mouse Macrophages
In order to dissect the molecular mechanisms mediating
this synergy, we examined the potential role of new
protein synthesis on MIG mRNA expression to determine
if TLR ligation was able to synergizewith IFN-g to induce
MIG without an intermediate protein. MH-S macrophages
were pretreated with the protein synthesis inhibitor
FIGURE 1 TLR ligands and IFN-g synergistically induce MIG mRNA
expression in macrophages. Northern analysis of mRNA from MH-S
macrophages stimulated with LPS (10ng/ml), zymosan (10mg/ml),
dsRNA (50mg/ml) or CpG (10mg/ml) þ/2 IFN-g (300U/ml) for 6h.
These data are representative of three experiments.
FIGURE 2 Dose response of LPS and IFN-g for MIG gene expression in macrophages. (A) Northern analysis of mRNA from MH-S macrophages
stimulated with increasing doses of LPS þ/2 IFN-g (300U/ml) for 6h. (B) Northern analysis of mRNA derived from MH-S cells stimulated with
increasing doses IFN-g þ/2 LPS (10ng/ml) for 6h. These data are representative of four experiments.
MIG INDUCTION BY TLR LIGATION AND IFN-g 79cycloheximide 10mg/ml (CHX) for 30min before the
addition of LPS (10ng/ml) and IFN-g (300U/ml) for 6h.
As seen in Fig. 3, CHX did not signiﬁcantly inhibit
MIG production by IFN-g or LPS þ IFN-g stimulated
macrophages (Fig. 3). Thus, the synergistic induction of
MIG gene expression by LPS and IFN-g does not require
new protein synthesis.
The Synergy between the TLR-4 Ligand LPS and
IFN-g on MIG Gene Expression is Independent of
TNF-a
It has been previously published that TNF-a and IFN-g
synergize to induce MIG mRNA in ﬁbroblasts (Ohmori
and Hamliton, 1995; Ohmori et al., 1997). Additionally, it
is well known that LPS can induce TNF-a expression by
mouse macrophages (Hiroi and Ohmori, 2003; Ohmori
and Hamliton, 1995; Ohmori and Hamilton, 1993).
While our data demonstrating that the synergy induced
by TLR ligation does not require new protein synthesis
suggests that TNF-a is not involved in enhancing MIG
expression, we further investigated the potential role of
TNF-a in the LPS and IFN-g induced synergy of MIG.
We isolated total RNA from LPS and IFN-g stimulated
thioglycollate elicited peritoneal macrophages from
TNF-a null mice as well as littermate controls (Marino
et al., 1997). As shown in Fig. 4, there was no difference in
the synergistic induction of MIG by LPS and IFN-g
despite the complete absence of TNF-a. Thus, unlike what
has been shown in ﬁbroblasts, the synergy between LPS
and IFN-g on MIG gene expression in macrophages is
independent of TNF-a expression. These data support the
concept that in macrophages direct TLR and IFN-g
signaling accounts for the synergy.
The Synergy between TLR Ligation and IFN-g on
MIG Expression Requires NF-kB
Inorder todeterminethe signaling pathwaysmediating the
synergy between TLR ligation and IFN-g on MIG
expression, we isolated total mRNA from MH-S
macrophages stimulated with the TLR-4 ligand LPS
þ/2 IFN-g in the presence of various inhibitors of signal
transduction. LPS is known to activate the MAP-kinase,
Protein Kinase C and NF-kB pathways. The synergy
between the LPS þ IFN-g on MIG expression was
inhibited by proteosome-1 10mg/ml (PS-1) (an inhibitor
of the NF-kB activation pathway) but not by rottlerin
3mg/ml(aproteinkinasecinhibitor),Wortmannin1mg/ml
(an inhibitor of PI-3 Kinase) or the MEK inhibitor
PD98059 2.5mg/ml (Fig. 5A). Interestingly, we found that
the induction of MIG by IFN-g alone was not inhibited by
PS-1 (Fig. 5B), suggesting that IFN-g-induced MIG was
not dependent on NF-kB activation. Additionally, similar
FIGURE 3 Effect of CHX on the synergy between HA and IFN-g on
MIG expression. MH-S macrophages were pretreated with CHX
(10mg/ml) for 30min before and during stimulation þ/2 LPS
(10ng/ml) and þ/2 IFN-g (300U/ml) for 6h. mRNA was isolated and
Northern analysis performed. These data are representative of four
identical experiments.
FIGURE 4 TNF-a is not required for the synergistic induction of MIG by LPS and IFN-g in primary peritoneal macrophages. mRNAwas isolated and
Northern analysis was performed on thioglycollate elicited peritoneal macrophages from TNF 2/2 and control C57BL6 mice stimulated with LPS
(10ng/ml) þ/2 IFN-g (300U/ml) for 6h. This is a representative blot of three identical experiments.
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ligands conﬁrming the need for NF-kB in mediating the
synergy(Fig.5B).ThusthedatainFig.5suggeststhatTLR
ligation-inducedNF-kBactivityplaysaroleinthesynergy
between TLR ligands and IFN-g on MIG transcription. Of
note, the cell viability was equivalent in cultures with and
without the inhibitors.
NF-kB p50/p50 Homodimers and p50/p65
Heterodimers Bind to the 2154 and 2129 NFkB-like
Sites on the 50 MIG Promoter
Given that there are the two NF-kB binding sites at 2154
and 2129 of the MIG promoter, we wanted to determine
ifTLRsignalingutilizedtheseMIGpromotersites.Firstwe
performed EMSAs of nuclear extracts from MH-S
macrophages stimulated with LPS þ/2 IFN-g for 1h.
Figure 6A demonstrates LPS induced binding of a complex
to the 2154 site that was competed away by unlabeled
consensus NF-kB probe butnot unlabeledconsensus STAT-
1a (note NF-kB appearing as two bands). In addition,
supershiftswithNF-kBp50andp65antibodiesshowthatthe
proteins binding tothe 2154 siteconsisted of both p50/p50
homodimers and p50/p65 heterodimers. The anti-p50
antibodysupershifts bothbands while the anti-p65antibody
only supershifts the lower band. As a control, anti-p52
antibody failed to supershift either band. Furthermore, this
NF-kBbindingwasspeciﬁcinthatnobindingwasobserved
in EMSAs using a probe containing a 2bp mutation at the
2154 site (2154M) (Fig. 6A).
FIGURE 5 The synergy between TLR ligands and IFN-g on MIG expression requires NF-kB. MH-S macrophages were stimulated with LPS
(10ng/ml) þ/2 IFN-g (300U/ml) for 6h in the presence or absence of the indicated inhibitors: PS-1 10mg/ml, PD98059 2.5mg/ml, rottlerin 1mg/ml
and wortmannin 3mg/ml (A) or TLR ligands (zymosan 10mg/ml, dsRNA 50mg/ml, LPS 10ng/ml or CpG 10mg/ml) þ IFN-g (300U/ml) þ PS-1
(10mg/ml) for 6h (B). RNA was isolated and Northern analysis was performed. This experiment is representative of three identical experiments.
FIGURE 6 NF-kB p50/p50 homodimers and p50/p65 heterodimers bind to the 2154 and 2129 NFkB-like sites on the 50 MIG promoter. EMSAwas
performed using nuclear extracts from MH-S macrophages stimulated with LPS (10ng/ml) þ/2 IFN-g (300U/ml) for 1h and radiolabeled DNA probes
from the MIG promoter containing the 2154 (A) or 2129 (B) NF-kB-like site or a mutant 2154 site (A) or mutant 2129 (B) sites. Competition was
performed with unlabeled probes consisting of consensus NF-kBo rS T A T - 1 a and supershifts with the indicated antibodies. This experiment is
representative of four identical experiments.
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using a 22bp DNA probe containing the 2129 site from
the MIG promoter and nuclear extracts from MH-S
macrophages stimulated with LPS þ/2 IFN-g for 1h.
Using the 2129 probe, LPS induced the up-regulation of a
protein-DNA complex that was competed away by
unlabeled consensus NF-kB but not unlabeled consensus
STAT-1a probes. This complex was also supershifted by
antibodies to p50 and p65 but not STAT-1a indicating the
presence of both p50/p50 and p50/p65 dimers (Fig. 6B).
Furthermore, the speciﬁcity of NF-kB binding to this site
was conﬁrmed by the inability of -129M probe (identical
probe except for a 2bp mutation at the predicted NF-kB
binding site) to bind the protein complex (Fig. 6B).
Interestingly, there is also a faint band running at the same
level as the NF-kB using either the 2129 and 2154
probes in the unstimulated and IFN-g alone stimulated
conditions (Figs. 6A and B) that is competed with
unlabeled consensus NF-kB (data not shown). These
data along with our previously published results, suggest
that even in resting or IFN-g alone treated cells, NF-kB
family members are constitutively expressed (Horton
et al., 2002).
Both the 2154 and 2129 NF-kB-like Sites on the MIG
Promoter are Necessary for the Synergistic Induction
of MIG Expression by LPS 1 IFN-g as well as for
Maximal Induction of MIG by IFN-g Alone
Thus far we have demonstrated that the TLR-4 ligand LPS
was able to induce NF-kB binding at two sites on the
proximal MIG promoter. In order to determine the
functional signiﬁcance of LPS-induced NF-kB proteins
binding to the 2154 and 2129 sites of the MIG promoter,
we used transient transfection assays. We designed
promoter constructs containing the wild type 2284 to
þ43 fragment of the MIG promoter upstream of a ﬁreﬂy
luciferase reporter gene (p284) or constructs containing
mutations in the 2154 (pM154), 2129 (pM129) and both
2154 and 2129 (pM129/154) NF-kB-like sites identical
to the mutant probes used in the EMSA studies. Mutations
at the individual NF-kB-like sites did not inhibit
the synergy between LPS and IFN-g but mutations at
both the 2154 and 2129 sites completely eliminated the
synergy (Fig. 7). Additionally, transfection assays using a
construct containing four copies of the g-responsive
element-1 (gRE-1) alone upstream of a ﬁreﬂy luciferase
reporter also failed to demonstrate the synergy induced by
LPS and IFN-g indicating that the gRE-1 is not sufﬁcient
to mediate the synergy (data not shown).
Surprisingly mutations at the 2154 and 2129
sites (individually and combined) decreased the induction
of MIG expression by IFN-g alone. There was a
signiﬁcant inhibition of IFN-g induced MIG between the
wild type promoter construct p284 and the mutants: pM154
ðp ¼ 0:0157Þ; pM129 ðp ¼ 0:003Þ; and pM129/154
ðp , 0:0001Þ: The inhibition was greatest in the dual
2154 and 2129 mutated construct, butwas still signiﬁcant
in the 2129 mutant and to a lesser degree in the 2154
mutant.Furthermore,theconstructcontainingfourcopiesof
the gRE-1 alone, with no NF-kB-like sites, also demon-
strated decreased response to IFN-g stimulation (data not
shown). These transfection studies support the notion
that NF-kB binding at both the 2154 and 2129 sites
is necessary for the synergistic induction of MIG by LPS
and IFN-g. Furthermore, they indicate that these cis
elements may play a role in the maximal induction of
MIG by IFN-g alone.
NF-kB p50 Helps Mediate the Synergy between LPS
and IFN-g on MIG Expression in Macrophages
The inhibitor, EMSA and transfection data in Figs. 5–7
suggest that the 2154 and 2129 NF-kB binding sites are
necessary for both the synergy between LPS and IFN-g on
MIG expression as well as the induction of MIG by IFN-g
alone. Thus, we wanted to evaluate the role of NF-kB p50
proteins in mediating the synergy between LPS and
IFN-g. To do this, Northern analysis was performed on
total RNA from thioglycollate elicited peritoneal macro-
phages from NF-kB p50 null mice stimulated with varying
doses of LPS þ/2 IFN-g. As seen in Fig. 8, there was
a shift in the dose response curve for induction of MIG
mRNA by LPS and IFN-g. Low doses of IFN-g did not
FIGURE 7 The 2154 and 2129 NF-kB-like sites are necessary for synergy between LPS and IFN g as well as the induction of MIG by IFN-g alone.
MH-S macrophages were transfected with constructs containing 284bp of the 50 MIG promoter þ/2 point mutations in the 2154 (pM154), the 2129
(pM129) or the 2154 þ 2 129 (pM154/129) sites upstream of a luciferase reporter. Transfected cells were stimulated with LPS (10ng/ml) þ/2 IFN-g
(300U/ml) for 18h. Promoter activity was assayed by luciferase activity. These data are the result of four identical experiments.
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mice, but 10U of IFN-g þ 0.1ng/ml of LPS markedly
induced MIG in control mice where as it had a minimal
effect on cells from the NF-kB p50 null mice. In fact, faint
induction of MIG was present in control mice with as little
as 1U of IFN-g þ 0.1ng/ml of LPS (Fig. 8). These data
suggest that the NF-kB p50 member plays a critical (non-
redundant) role in both IFN-g-induced and IFN-g þ LPS-
induced MIG expression.
DISCUSSION
MIG was originally described in both humans and mice as
a gene speciﬁcally induced by IFN-g (Farber, 1990,1992,
1993). By binding to its receptor CXCR3, MIG attracts
both CD4þ and CD8þ T cells and has been implicated
in contributing to the host inﬂammatory response
against infection and tumor immunity (Liao et al., 1995;
Strieter et al., 1995). It is also involved in the pathogenesis
of a number of autoimmune disorders as well as the
development of atherosclerosis (Liu et al., 2001; Belperio
et al., 2002; Mahad et al., 2002; Yun et al., 2002).
Recently, by examining MIG null mice, Park et al., have
revealed a role for MIG in skewing toward a TH1 immune
response as well as contributing to the optimal generation
of humoral immune responses to intracellular bacterial
infections (Park et al., 2002). In addition, this group has
shown that IFN-g can induce MIG in dendritic cells
(Park et al., 2002). Taken together, these data implicate
MIG as playing a key role in the adaptive immune
response by recruiting T cells and enhancing
their interactions with B cells and dendritic cells (Park
et al., 2002).
Our experiments sought to dissect the transcriptional
mechanisms by which signals from pathogens and the
host cooperate to enhance the immune response.
The data clearly demonstrate the ability of bacterial,
viral and mycotic products to enhance MIG expression.
In particular, while low doses of IFN-g fail to induce MIG,
the addition of these infectious products results in
substantial MIG production. At the molecular level, the
integration of cellular signals (IFN-g) and infectious
signals (TLR ligation) was mediated by STAT1a and
NF-kB, respectively. Pharmacologic inhibition of NF-kB
activation inhibited this synergy and the synergy was
markedly decreased in macrophages derived from p50 KO
mice. Additionally, by mutating the proximal MIG
promoter, we demonstrated a key role for the 2154 and
2129 NF-kB binding sites in facilitating the ability of
LPS to enhance IFN-g-induced MIG expression. Further-
more, the transfection studies identiﬁed the 2154 and
2129 sites were important to the induction of MIG by
IFN-g alone (Fig. 7).
In this report we demonstrate that the maximal
production of the T cell attractant MIG by macrophages
is the result of the collaboration between Toll-like receptor
engagement and IFN-g. Although it has been previously
shown that TNF-a can synergize with IFN-g to promote
MIG production by ﬁbroblasts, the synergy induced by
TLR-ligation on macrophages is direct and independent of
TNF-a. Given that the ligands for the TLRs are
byproducts of infectious agents such as bacteria, viruses
and fungi, these observations deﬁne another mechanism
whereby the innate immune response serves to promote
adaptive immunity. The inability of TLR engagement
alone to induce MIG suggests that in the absence of IFN-g
(presumably initially produced by NK cells) the recruit-
ment of T cells by MIG to the site of infection does not
occur. Means et al., noted that the TLR 5 ligand bacterial
ﬂagellin could only induce MIG production from dendritic
cells in conjunction with autocrine IFN-b (Means et al.,
2003). Our data are different in that in both the
macrophage cell line and the primary macrophages,
TLR 2, 3, 4 and 9 engagement alone did not induce MIG.
Despite the fact that CpG is known to cause the induction
FIGURE8 NF-kB p50 is required forthe synergistic inductionof MIGby LPS and IFN-g.mRNAwas isolatedand Northernanalysis wasperformed on
thioglycollate elicited peritoneal macrophages from NF-kB p50 null or control mice stimulated with LPS (0.1ng/ml) þ/2 IFN g (1 or 10U/ml) for 6h.
This is a representative blot of three identical experiments.
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for IFN-g in terms of the synergy (Means et al., 2003).
Thus, perhaps the role of MIG in promoting autoimmunity
is due in part to the dysregulation of this two signal
requirement. For example, a genetic predisposition to
loosely regulate IFN-g may result in the inappropriate
induction of MIG in the setting of TLR ligation and thus
the recruitment of T cells to target organs.
The molecular pathways described here also have
potential clinical implications. First, MIG has been
implicated in playing a role in a number of autoimmune
disorders (Belperio et al., 2002; Mahad et al., 2002;
Yun et al., 2002). The critical role of NF-kB in the
production of maximal MIG suggests that pharmacologic
inhibition of NF-kB activation may not only lead to a
decrease in inﬂammation in general but also may serve
to decrease MIG mediated recruitment to target organs.
In this regard, NF-kB inhibitors such as PS-341 (Velcade)
have already been approved for human use (Twombly,
2003). It will be interesting to determine if in certain
animal models of autoimmunity such inhibitors have the
ability to decrease MIG expression. Alternatively, MIG
has also been implicated in the anti-tumor immune
response (Ruehlmann et al., 2001). Thus, as many of the
TLR agonists such CpG are being pursued as adjuvants in
immunotherapy, it is possible that their effects are in part
through the up-regulation of MIG.
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